OSTX Form 4 reports acquisition/exercise transactions

McKean-Dieser Avril Suzette reported acquisition or exercise transactions in a Form 4 filing for OSTX.

Rhea-AI Filing Summary

McKean-Dieser Avril Suzette reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 2 txns

Insider McKean-Dieser Avril Suzette

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy)	50,000	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock options (right to buy) — 50,000 contracts (Direct); Common Stock — 5,000 shares (Direct)

Footnotes (1)

1. F1. On January 22, 2026, the reporting person was granted options to purchase 50,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OS Therapies (OSTX) report for Avril McKean-Dieser?

OS Therapies reported a stock option grant to director Avril McKean-Dieser. On January 22, 2026, she received options to buy 50,000 shares of common stock at an exercise price of $1.34 per share under a stock option award agreement.

How many OS Therapies (OSTX) stock options were granted to the director?

The director received 50,000 stock options. These options allow Avril McKean-Dieser to purchase 50,000 shares of OS Therapies common stock at an exercise price of $1.34 per share, subject to the vesting conditions described in the award agreement.

When do Avril McKean-Dieser’s OS Therapies (OSTX) options vest?

The options vest in full one year after the grant date. All 50,000 options granted on January 22, 2026 will vest on the one-year anniversary of that date, provided she continues serving as a director of OS Therapies at that time.

What are Avril McKean-Dieser’s OS Therapies (OSTX) holdings after the Form 4?

After the reported transaction, she holds shares and options. The filing shows she directly owns 5,000 shares of OS Therapies common stock and 50,000 stock options granted on January 22, 2026, each option exercisable for one share of common stock.

What is the exercise price of the OS Therapies (OSTX) stock options granted?

The stock options have an exercise price of $1.34 per share. This means Avril McKean-Dieser can purchase OS Therapies common stock at $1.34 per share upon exercising the 50,000 options after they vest according to the award terms.

Is Avril McKean-Dieser an officer or only a director at OS Therapies (OSTX)?

She is reported as a director of OS Therapies. The filing identifies Avril McKean-Dieser as a director and not as an officer or 10% owner, and the option grant is tied to her service on the company’s board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:43 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKean-Dieser Avril Suzette

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MD 21638

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								5,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.34	01/22/2026		A		50,000		(1)	01/22/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. On January 22, 2026, the reporting person was granted options to purchase 50,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on such date.

	/s/ Avril McKean-Dieser	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.